Detalhe da pesquisa
1.
Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study.
Haematologica
; 109(3): 895-905, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37646660
2.
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network.
Lancet Oncol
; 24(6): e255-e269, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37269857
3.
Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial.
Am J Hematol
; 97(4): 481-490, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35089607
4.
Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(6): 801-812, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34087126
5.
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial.
Lancet
; 396(10262): 1563-1573, 2020 11 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-33189178
6.
A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome.
Haematologica
; 105(1): 201-208, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31278209
7.
Is it possible to improve prognostic value of NCCN-IPI in patients with diffuse large B cell lymphoma? The prognostic significance of comorbidities.
Ann Hematol
; 97(2): 267-276, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-29130134
8.
25(OH) vitamin D deficiency in lymphoid malignancies, its prevalence and significance. Are we fully aware of it?
Support Care Cancer
; 26(8): 2825-2832, 2018 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-29511954
9.
Late relapse of Hodgkin's lymphoma - is it different in clinical characteristics and outcome?
J BUON
; 22(2): 481-486, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28534373
10.
A real world multicenter retrospective study on extramedullary disease from Balkan Myeloma Study Group and Barcelona University: analysis of parameters that improve outcome.
Haematologica
; 106(4): 1228, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33792227
11.
Development and validation of multivariable predictive model for thromboembolic events in lymphoma patients.
Am J Hematol
; 91(10): 1014-9, 2016 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-27380861
12.
The possible benefit from total tumour resection in primary diffuse large B-cell lymphoma of central nervous system - a one-decade single-centre experience.
Br J Neurosurg
; 30(1): 80-5, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26337736
13.
Gene Mutation Profiles in Primary Diffuse Large B Cell Lymphoma of Central Nervous System: Next Generation Sequencing Analyses.
Int J Mol Sci
; 17(5)2016 May 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-27164089
14.
A single institution experience on 314 newly diagnosed advanced Hodgkin lymphoma patients: the role of ABVD in daily practice.
Eur J Haematol
; 93(5): 392-9, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24797378
15.
The effect of paraprotein on platelet aggregation.
J Clin Lab Anal
; 28(2): 141-6, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-24395751
16.
Does Double Mean Trouble? Coexistence of Myeloproliferative and Lymphoproliferative Neoplasms.
J Clin Med
; 13(6)2024 Mar 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-38542040
17.
Specific binding of paraprotein to platelet receptors as a cause of platelet dysfunction in monoclonal gammopathies.
Acta Haematol
; 130(2): 101-7, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23548666
18.
Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial.
Lancet Haematol
; 10(10): e813-e824, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37793772
19.
Hypothalamic dysfunction in a patient with primary lymphoma of the central nervous system.
Neurol Sci
; 33(2): 387-90, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-21822693
20.
Salvage Therapy With Polatuzumab Vedotin, Bendamustine, and Rituximab Prior to Allogeneic Hematopoietic Transplantation in Patients With Aggressive Lymphomas Relapsing After Therapy With Chimeric Antigen Receptor T-Cells-Report on Two Cases.
Front Oncol
; 11: 737645, 2021.
Artigo
em Inglês
| MEDLINE | ID: mdl-34604075